MCID: SPC010
MIFTS: 42

Speech and Communication Disorders

Categories: Mental diseases

Aliases & Classifications for Speech and Communication Disorders

MalaCards integrated aliases for Speech and Communication Disorders:

Name: Speech and Communication Disorders 39 41
Communication Disorder 39 12 14
Language Disorders 52 42 69
Language Disorder 39 12 14
Communication Disorders 52 42
Speech and Language Disorder 69
Speech Language Disorder 39
Communication Impairment 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2033 DOID:93
ICD10 33 F80.9
NCIt 47 C2958 C97155

Summaries for Speech and Communication Disorders

MedlinePlus : 41 many disorders can affect our ability to speak and communicate. they range from saying sounds incorrectly to being completely unable to speak or understand speech. causes include hearing disorders and deafness voice problems, such as dysphonia or those caused by cleft lip or palate speech problems like stuttering developmental disabilities learning disorders autism spectrum disorder brain injury stroke some speech and communication problems may be genetic. often, no one knows the causes. by first grade, about 5 percent of children have noticeable speech disorders. speech and language therapy can help. nih: national institute on deafness and other communication disorders

MalaCards based summary : Speech and Communication Disorders, also known as communication disorder, is related to acquired purpura fulminans and childhood-onset nemaline myopathy, and has symptoms including lethargy, neurobehavioral manifestations and aprosodia. An important gene associated with Speech and Communication Disorders is FOXP2 (Forkhead Box P2), and among its related pathways/superpathways are Neuroscience and Alzheimers Disease Pathway. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and tongue, and related phenotypes are cellular and behavior/neurological

Disease Ontology : 12 A specific developmental disorder that involves specific developmental disorders of speech and language.

Wikipedia : 72 A communication disorder is any disorder that affects an individual\'s ability to comprehend, detect, or... more...

Related Diseases for Speech and Communication Disorders

Diseases related to Speech and Communication Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Related Disease Score Top Affiliating Genes
1 acquired purpura fulminans 10.9 APOE MAPT
2 childhood-onset nemaline myopathy 10.8 CNTNAP2 FOXP2
3 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.8 GRN PSEN1
4 simultanagnosia 10.8 GRN PSEN1 TARDBP
5 cerebral arteritis 10.8 FOXP2 PSEN1 TARDBP
6 autotopagnosia 10.8 GRN PSEN1 TARDBP
7 urethritis 10.8 APOE PSEN1 TARDBP
8 glucose metabolism disease 10.8 CBS GRN PSEN1
9 autoimmune disease of urogenital tract 10.8 GRN PSEN1
10 ceroid lipofuscinosis, neuronal, 11 10.8 GRN MAPT TARDBP
11 apperceptive agnosia 10.8 GRN PLG
12 limited scleroderma 10.7 APOE MAPT PSEN1
13 cluttering 10.7
14 meckel syndrome 10 10.7 APOE MAPT PSEN1
15 speech disorder 10.7
16 mixed receptive-expressive language disorder 10.7
17 perry syndrome 10.7 C9orf72 GRN TARDBP
18 mast syndrome 10.7 C9orf72 MAPT TARDBP
19 seow najjar syndrome 10.6 APOE GRN MAPT TARDBP
20 hyperglycemia 10.6 CNTNAP2 GRN
21 carotid body cancer 10.6 APOE MAPT PSEN1
22 intracranial thrombosis 10.6 CNTNAP2 FOXP2 GNPTG
23 retinitis pigmentosa 13 10.6 C9orf72 TARDBP
24 simpson-golabi-behmel syndrome 10.6 CNTNAP2 FOXP2 GNPTG
25 scrub typhus 10.6 CNTNAP2 FOXP2 KIAA0319
26 supranuclear palsy, progressive atypical 10.6 APOE CBS GRN MAPT
27 propriospinal myoclonus 10.6 C9orf72 GRN MAPT PSEN1
28 isolated focal cortical dysplasia type ic 10.6 C9orf72 GRN MAPT PSEN1
29 cardiomyopathy, dilated, 1u 10.6 APOE MAPT PSEN1 TARDBP
30 riedel's fibrosing thyroiditis 10.6 MAPT TARDBP
31 allergic bronchopulmonary aspergillosis, familial 10.5 APOE MAPT TARDBP
32 intracranial structure hemangioma 10.5 MAPT PSEN1
33 acoustic neuroma 10.5
34 agnosia 10.5
35 meniere's disease 10.5
36 usher syndrome 10.5
37 stuttering 10.5
38 expressive language disorder 10.5
39 atypical autism 10.5 CNTNAP2 FOXP2 MECP2
40 neuromyotonia and axonal neuropathy, autosomal recessive 10.5 C9orf72 TARDBP
41 3mc syndrome 10.5 CBS GRN MAPT PSEN1 TARDBP
42 submandibular adenitis 10.5 CBS GRN MAPT PSEN1 TARDBP
43 parkinson disease 1 10.5 APOE GRN MAPT PSEN1 TARDBP
44 mucopolysaccharidosis iii 10.5 C9orf72 GRN MAPT TARDBP
45 diffuse alopecia areata 10.5 GRN PSEN1
46 auditory agnosia 10.5 APOE C9orf72 FOXP2 GRN MAPT
47 akinetic mutism 10.4 APOE CBS GRN MECP2 PSEN1
48 evans' syndrome 10.4 KIAA0319 MAPT MECP2
49 melanoma, cutaneous malignant, 2 10.4 C9orf72 CBS GRN PSEN1 TARDBP
50 long qt syndrome 5 10.3 C9orf72 GRN MAPT PSEN1 TARDBP

Graphical network of the top 20 diseases related to Speech and Communication Disorders:



Diseases related to Speech and Communication Disorders

Symptoms & Phenotypes for Speech and Communication Disorders

UMLS symptoms related to Speech and Communication Disorders:


lethargy, neurobehavioral manifestations, aprosodia, reduced consciousness/confusion, other symbolic dysfunction

MGI Mouse Phenotypes related to Speech and Communication Disorders:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 APOE C9orf72 CNTNAP2 GRN L1CAM MAPT
2 behavior/neurological MP:0005386 10.13 CNTNAP2 GRN L1CAM MAPT MECP2 PSEN1
3 growth/size/body region MP:0005378 10.11 APOE C9orf72 CNTNAP2 L1CAM MAPT MECP2
4 immune system MP:0005387 9.97 APOE C9orf72 GRN MAPT MECP2 PLG
5 nervous system MP:0003631 9.9 APOE C9orf72 CNTNAP2 GRN L1CAM MAPT
6 integument MP:0010771 9.86 APOE CNTNAP2 L1CAM MAPT MECP2 PLG
7 no phenotypic analysis MP:0003012 9.56 MECP2 TARDBP TRPV1 APOE C9orf72 GRN
8 taste/olfaction MP:0005394 8.92 APOE CNTNAP2 MAPT TRPV1

Drugs & Therapeutics for Speech and Communication Disorders

Drugs for Speech and Communication Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4 19982-08-2 4054
3
Norepinephrine Approved Phase 4 51-41-2 439260
4
Donepezil Approved Phase 4 120014-06-4 3152
5
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
6 Antiparkinson Agents Phase 4,Phase 2,Phase 3
7 Dopamine Agents Phase 4,Phase 2,Phase 3
8 Excitatory Amino Acid Antagonists Phase 4
9 Excitatory Amino Acids Phase 4
10 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
11 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
12 Nootropic Agents Phase 4,Phase 2,Phase 1
13 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antidepressive Agents Phase 4
15 Antidepressive Agents, Second-Generation Phase 4
16 Psychotropic Drugs Phase 4,Phase 2,Phase 3
17
Serotonin Phase 4,Phase 3 50-67-9 5202
18 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
19 Venlafaxine Hydrochloride Phase 4
20 Cholinergic Agents Phase 4,Phase 3
21 Cholinesterase Inhibitors Phase 4,Phase 3
22 Angiotensin-Converting Enzyme Inhibitors Phase 4
23 Antihypertensive Agents Phase 4
24 HIV Protease Inhibitors Phase 4
25
protease inhibitors Phase 4
26
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359 38101
27
Levodopa Approved Phase 2, Phase 3 59-92-7 6047
28
Rivastigmine Approved, Investigational Phase 3 123441-03-2 77991
29
Ethanol Approved Phase 2, Phase 3 64-17-5 702
30
Sodium oxybate Approved Phase 2, Phase 3 502-85-2 5360545
31
Asenapine Approved Phase 3 85650-56-2, 65576-45-6 3001386
32 Ecopipam Investigational Phase 2, Phase 3 112108-01-7
33 Neuroprotective Agents Phase 3,Phase 2,Phase 1
34 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2, Phase 3
35 Carbidopa, levodopa drug combination Phase 2, Phase 3
36 Central Nervous System Depressants Phase 2, Phase 3
37 Tranquilizing Agents Phase 2, Phase 3
38 Anesthetics Phase 2, Phase 3
39 Antipsychotic Agents Phase 2, Phase 3
40 Dopamine Antagonists Phase 2, Phase 3
41 Adjuvants, Anesthesia Phase 2, Phase 3
42 Anesthetics, General Phase 2, Phase 3
43 Anesthetics, Intravenous Phase 2, Phase 3
44 Anti-Infective Agents Phase 2, Phase 3
45 Anti-Infective Agents, Local Phase 2, Phase 3
46
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
47 adderall Phase 2
48 Central Nervous System Stimulants Phase 2
49 Dopamine Uptake Inhibitors Phase 2
50 Cerebrolysin Phase 2

Interventional clinical trials:

(show top 50) (show all 284)

id Name Status NCT ID Phase Drugs
1 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
2 Neuromuscular Electroestimulation and Respiratory Muscle Training in Subacute Stroke Completed NCT02473432 Phase 4
3 Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease Completed NCT00469456 Phase 4 Memantine;placebo
4 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
5 Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program Completed NCT00401726 Phase 4 Venlafaxine ER
6 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
7 Drug to Prevent Pneumonia in the Tube Fed Terminated NCT02358642 Phase 4 Angiotensin converting enzyme inhibitor (Lisinopril);Placebo
8 Randomized Clinical Trial of Phonological Interventions Unknown status NCT00818428 Phase 2, Phase 3
9 Effectiveness of Early Parent-Based Language Intervention Unknown status NCT00625261 Phase 3
10 Effects of OroPharyngeal Exercises on Patients With Moderate Obstructive Sleep Apnea Completed NCT00660777 Phase 3
11 A Comparison of Language Intervention Programs Completed NCT00033150 Phase 3
12 Balance Training in Parkinson's Disease Using Cues Completed NCT01960985 Phase 3
13 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
14 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
15 Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Recruiting NCT02909088 Phase 2, Phase 3 Ecopipam 50mg;Ecopipam 100mg
16 Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Recruiting NCT02839642 Phase 3 Rivastigmine;Placebo
17 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Recruiting NCT02241213 Phase 3
18 Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor Active, not recruiting NCT03292458 Phase 2, Phase 3 Sodium Oxybate
19 A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering Suspended NCT01684657 Phase 3 Asenapine
20 Surgery for Vocal Cord Paralysis Terminated NCT00064571 Phase 3
21 Swallowing Rehabilitation of Dysphagic Tracheostomized Patients Under Mechanical Ventilation at ICU Unknown status NCT01496924 Phase 2
22 Dextroamphetamine and tDCS to Improve the Fluency Unknown status NCT02514044 Phase 2 Dexedrine;Placebo
23 Efficacy of Voice Treatment for Parkinson's Disease Unknown status NCT00123084 Phase 2
24 Deep rTMS (Repetitive Transcranial Magnetic Stimulation)for Treatment of Autism Symptoms in Children. Unknown status NCT01388179 Phase 2
25 Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy Unknown status NCT02116348 Phase 2 Cerebrolysin (Nerve growth factor)
26 Effectiveness of Anthroposophic Speech Therapy in Patients With Asthma Completed NCT02501824 Phase 2
27 The Development of Autistic Children Based on Mothers´Response in Autism Behavior Checklist Completed NCT00725556 Phase 1, Phase 2
28 An Autism Study Using Nambudripad's Food Allergy Elimination Treatments Completed NCT00247156 Phase 1, Phase 2
29 Emotional Prosody Treatment in Parkinson's Completed NCT01956266 Phase 1, Phase 2
30 RCT: Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury Completed NCT02209935 Phase 2
31 Building Complex Language Completed NCT01337232 Phase 1, Phase 2
32 Efficacy of AMALS in Treating Language Impairment in Children Completed NCT00840060 Phase 2
33 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra
34 Can Acupuncture Benefit Surgical Patients With Haemorrhagic Stroke? Completed NCT01037894 Phase 1, Phase 2
35 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
36 The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
37 Low Power Laser and Exercise in Osteoarthritis of the Knee: a Randomized Clinical Trial Completed NCT01306435 Phase 2
38 Expiratory Muscle Training in Patients With Parkinson's Disease Completed NCT00843739 Phase 1, Phase 2
39 Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
40 Randomised Controlled Treatment Study of Selective Mutism Completed NCT01002196 Phase 2
41 Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS) Completed NCT00239915 Phase 2 Pagoclone
42 Effects of Transcranial Direct Current Stimulation in Post-stroke Aphasia Recruiting NCT02622945 Phase 2
43 Brain Connectivity Supporting Language Recovery in Aphasia Recruiting NCT02416856 Phase 2
44 Brain Stimulation and Aphasia Treatment Recruiting NCT01686373 Phase 2
45 Furlow Palatoplasty With Tensor Tenopexy Recruiting NCT01535131 Phase 2
46 Evaluating Anodal tDCS Preceding Aphasia Therapy Recruiting NCT02249819 Phase 1, Phase 2
47 tDCS and Aphasia Therapy in the Acute Phase After Stroke Recruiting NCT03297450 Phase 2
48 Effects of Transcranial Direct Current Stimulation (tDCS) on Patients With Chronic Orofacial Pain Terminated NCT01883245 Phase 2
49 Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss Terminated NCT02414152 Phase 1, Phase 2 anakinra
50 Treatment for Word Retrieval Impairments in Aphasia Unknown status NCT00764400 Phase 1

Search NIH Clinical Center for Speech and Communication Disorders

Cochrane evidence based reviews: communication disorders

Genetic Tests for Speech and Communication Disorders

Anatomical Context for Speech and Communication Disorders

MalaCards organs/tissues related to Speech and Communication Disorders:

39
Brain, Testes, Tongue, Heart, Kidney, Cortex

Publications for Speech and Communication Disorders

Variations for Speech and Communication Disorders

Expression for Speech and Communication Disorders

Search GEO for disease gene expression data for Speech and Communication Disorders.

Pathways for Speech and Communication Disorders

Pathways related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.61 APOE CNTNAP2 MAPT MECP2 PSEN1 TARDBP
2 10.79 APOE MAPT PSEN1
3 10.57 PLG PSEN1

GO Terms for Speech and Communication Disorders

Cellular components related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.56 CNTNAP2 L1CAM MAPT PSEN1
2 growth cone GO:0030426 9.5 L1CAM MAPT PSEN1
3 dendrite GO:0030425 9.43 APOE CNTNAP2 L1CAM MAPT PSEN1 TRPV1
4 axolemma GO:0030673 9.16 CNTNAP2 MAPT
5 neuronal cell body GO:0043025 9.1 APOE CNTNAP2 L1CAM MAPT PSEN1 TRPV1

Biological processes related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 post-embryonic development GO:0009791 9.61 FOXP2 MECP2 PSEN1
2 cerebral cortex development GO:0021987 9.54 CNTNAP2 FOXP2 PSEN1
3 memory GO:0007613 9.5 MAPT MECP2 PSEN1
4 microglial cell activation GO:0001774 9.46 MAPT TRPV1
5 amyloid precursor protein metabolic process GO:0042982 9.4 APOE PSEN1
6 vocal learning GO:0042297 9.16 CNTNAP2 FOXP2
7 astrocyte activation GO:0048143 8.96 MAPT
8 synapse organization GO:0050808 8.96 L1CAM MAPT
9 neuron projection development GO:0031175 8.92 CNTNAP2 L1CAM MAPT MECP2

Molecular functions related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 APOE CBS MAPT TARDBP TRPV1 USP15
2 apolipoprotein binding GO:0034185 9.16 MAPT PLG
3 lipoprotein particle binding GO:0071813 8.62 APOE MAPT

Sources for Speech and Communication Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....